[
  {
    "ts": null,
    "headline": "UPS Stock Joins 7% Dividend Yielders in S&P 500. Here’s Who Else Is in That Club.",
    "summary": "United Parcel Service  has joined the 7% yield club in the S&P 500.  The stock’s yield surpassed that rare level on Tuesday, after the logistics company’s disappointing second-quarter profit report triggered a 10% slide in the shares.  There are now four others in the index with 7%-plus yields:  Pfizer Conagra Brands LyondellBasell Industries  and  Healthpeak Properties  according to data from S&P Dow Jones Indices.",
    "url": "https://finnhub.io/api/news?id=eb37ece2f923860ffc715500fe154272db9099640ee329beab8fc1800eca51a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753905720,
      "headline": "UPS Stock Joins 7% Dividend Yielders in S&P 500. Here’s Who Else Is in That Club.",
      "id": 136149086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "United Parcel Service  has joined the 7% yield club in the S&P 500.  The stock’s yield surpassed that rare level on Tuesday, after the logistics company’s disappointing second-quarter profit report triggered a 10% slide in the shares.  There are now four others in the index with 7%-plus yields:  Pfizer Conagra Brands LyondellBasell Industries  and  Healthpeak Properties  according to data from S&P Dow Jones Indices.",
      "url": "https://finnhub.io/api/news?id=eb37ece2f923860ffc715500fe154272db9099640ee329beab8fc1800eca51a2"
    }
  },
  {
    "ts": null,
    "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs",
    "summary": "My monthly update and commentary on the top dividend stock picks from Barron's Better Bets, July 2025 edition. Read the full report and list of stock picks here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=cc3202f910fad429e65e4e084470664a3bacf73b25553a48119447c6c2f00981",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753898358,
      "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs",
      "id": 136146370,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/78455762/image_78455762.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "My monthly update and commentary on the top dividend stock picks from Barron's Better Bets, July 2025 edition. Read the full report and list of stock picks here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=cc3202f910fad429e65e4e084470664a3bacf73b25553a48119447c6c2f00981"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 11 Innovative Dividend Stocks to Buy Now. The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid popularity thanks to its effectiveness. One of its founders, Erhart, drew on his background in candy-making to add an almond-toffee flavor, making the […]",
    "url": "https://finnhub.io/api/news?id=d32c077e8cef0063723463b8408bb6c5615d557a6cb1a2ffe3401e3bd8599dc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753897158,
      "headline": "Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability",
      "id": 136148911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the 11 Innovative Dividend Stocks to Buy Now. The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid popularity thanks to its effectiveness. One of its founders, Erhart, drew on his background in candy-making to add an almond-toffee flavor, making the […]",
      "url": "https://finnhub.io/api/news?id=d32c077e8cef0063723463b8408bb6c5615d557a6cb1a2ffe3401e3bd8599dc3"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?",
    "summary": "AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.",
    "url": "https://finnhub.io/api/news?id=19034d13bf094b27d4de87764a7573cbe67d98efb9d9110d48e200f5cf68d1af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753880100,
      "headline": "Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?",
      "id": 136149059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.",
      "url": "https://finnhub.io/api/news?id=19034d13bf094b27d4de87764a7573cbe67d98efb9d9110d48e200f5cf68d1af"
    }
  },
  {
    "ts": null,
    "headline": "Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?",
    "summary": "MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.",
    "url": "https://finnhub.io/api/news?id=2bc4083672fe6b991f283c1307983699316e8018a6c4de9a1dfd83c88fb4f805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753879620,
      "headline": "Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?",
      "id": 136148954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.",
      "url": "https://finnhub.io/api/news?id=2bc4083672fe6b991f283c1307983699316e8018a6c4de9a1dfd83c88fb4f805"
    }
  },
  {
    "ts": null,
    "headline": "Time to Go Short on Pfizer (PFE)?",
    "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell […]",
    "url": "https://finnhub.io/api/news?id=74816e520ba86f4e28ee0e0340dcdd542069c0e0f46b5c763e3cea9790da730c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753877943,
      "headline": "Time to Go Short on Pfizer (PFE)?",
      "id": 136129994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell […]",
      "url": "https://finnhub.io/api/news?id=74816e520ba86f4e28ee0e0340dcdd542069c0e0f46b5c763e3cea9790da730c"
    }
  },
  {
    "ts": null,
    "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
    "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
    "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753866720,
      "headline": "Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical",
      "id": 136129851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high",
      "url": "https://finnhub.io/api/news?id=f4ed99d14bce5281098df11be77d3bd129145748873c855edeee129974794200"
    }
  }
]